Table 2 Participant’s data
From: COVID-19 mRNA vaccine and antibody response in lactating women: a prospective cohort study
Characteristics | Lactating women (n= 14) | Non-lactating women (n= 10) |
|---|---|---|
Maternal data | ||
Age Median ±SD | 33.7 ± 4.95 years | 34.5 ±10.6 years |
(minimum, maximum) years | 26-44 | 26-62 |
Caucasian n (%) | 14 (100%) | 10 (100%) |
Smoking habits n (%) | 1 (7.1%) | 1 (10%) |
Comorbidities n (%) | ||
No Comorbidities | 8 (57.1%) | 6 (60 %) |
Hypertension | 1 (7.1%) | 1 (10%) |
Asthma | 2 (14.3%) | - |
Dyslipidaemia | 1 (7.1%) | 1 (10%) |
Thyroid disorders | 1 (7.1%) | 1 (10%) |
Beta thalassemia | 1 (7.1%) | - |
Hodgkin lymphoma | - | 1 (10%) |
Side effects post vaccination n (%) | ||
Myalgia | 8 (57%) | 6 (60%) |
Headache | 6 (42.9) | 5 (50%) |
Local pain | 5 (35.7%) | 4 (40%) |
Nausea | 2 (14.3%) | 2 (20%) |
Fever | 1 (7.1%) | 2 (20%) |
Photophobia | 1 (7.1%) | 2 (20%) |
Tiredness | - | 3 (30%) |
Arthralgia | 1 (7.1%) | 2 (20%) |
Arm numbness | 1 (7.1%) | - |
Delivery data | NA | |
GA at delivery Median ±SD (Range) | 38.5 ± 1.7 weeks (range 34-41) | |
Mode of Delivery n (%) | ||
Caesarean | 5 (35.7%) | |
Vaginal | 9 (64.3%) | |
Infant and Breastfeeding data | NA | |
Birthweight (g) Median ±SD | 3263 ± 383 (2460-3800) | |
Percentile at the time of vaccination | 65.5±17 (range 50-97) | |
Breastfeeding duration n (%) | ||
≤ 2 - 12 months | 6 (42.85%) | |
≥ 12 - 24 months | 8 (57.14%) | |
Exclusive breastfeeding | 2 (14.28%) | |